Clinical trials: Antitumor Drug
Breast Cancer, Solid Tumor, Adult
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/HER2…
- Trial name
- NCT04946864
- Testing
- APG-2575, Palbociclib
- Where
- 7 sites in United States, China
- Volunteers
- 65 people
- Sponsor
- Ascentage Pharma Group Inc.
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP
To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug…
- Trial name
- NCT00000998
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal
Avelumab in Refractory Testicular Germ Cell Cancer.
This is a proof-of-concept study to define efficacy of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Conditions
- Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Testicular Diseases
- Trial name
- NCT03403777
- Testing
- Avelumab
- Where
- Slovakia
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute, Slovakia
Tumors
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of an investigational drug called DMXAA (5-6-dimethylxanthenone-4-acetic acid) or ASA404 when given together with carboplatin, paclitaxel and cetuximab to treat…
- Trial name
- NCT01031212
- Testing
- ASA404, Cetuximab, Carboplatin
- Where
- United States
- Sponsor
- University of California, San Francisco
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure.
- Conditions
- Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- FluBuBe (NCT04942730)
- Testing
- Fludarabine, Bendamustine Hydrochloride, Busulfan
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chemotherapeutic Agent Toxicity, Neuropathy
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary…
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain
- Trial name
- NCT02311907
- Testing
- Carboplatin, Glutathione, Laboratory Biomarker Analysis
- Where
- 390 sites in United States
- Volunteers
- 195 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Solid Tumor, Adult
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab.
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma
- Trial name
- KEYNOTE-E12 (NCT04443088)
- Testing
- INV-1120, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by…
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8
- Trial name
- NCT06900595
- Testing
- Biospecimen Collection, Cabozantinib, Cemiplimab
- Where
- 81 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
The primary purpose of this study is to prospectively determine whether capecitabine and 5-FU-induced toxicity is preventable by dose reduction prior to start of the first administration in patients heterozygous or homozygous…
- Trial name
- NCT00838370
- Testing
- Capecitabine, 5-fluorouracil
- Where
- 3 sites in Netherlands
- Volunteers
- 22 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07200830
- Testing
- Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring
- Where
- 142 sites in United States
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor…
- Trial name
- NCT04669899
- Testing
- JTX-8064, pimivalimab
- Where
- 45 sites in United States
- Volunteers
- 190 people
- Sponsor
- Jounce Therapeutics, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759587
- Testing
- Niraparib
- Where
- 27 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Chemotherapeutic Agent Toxicity, Neurotoxicity
Acute Pain Caused by Paclitaxel in Patients With Cancer
RATIONALE: Gathering information over time from patients receiving paclitaxel for cancer may help doctors learn more about pain caused by paclitaxel and plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00860041
- Testing
- pain questionnaires
- Where
- 279 sites in United States
- Volunteers
- 306 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04579224
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 448 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
Age-Related Macular Degeneration
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related…
- Trial name
- NCT05984927
- Testing
- NG101 AAV gene therapy
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Elisigen, Inc.
Advanced Solid Tumor
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.
- Trial name
- NCT07896460
- Testing
- BG-92505, Anti-Cancer Agent
- Volunteers
- 137 people
- Sponsor
- BeOne Medicines
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Antineoplastic Chemotherapy Induced Anemia
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
The purpose of this study is to assess safety and efficacy of weekly epoetin alfa (Hemax® ) administered for 12 weeks in patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl) undergoing palliative…
- Trial name
- NCT01374373
- Testing
- Epoetin alfa
- Where
- 3 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Bio Sidus SA